Abstract GATA2 is a pioneering transcription factor governing androgen receptor expression and signaling in prostate cells. To understand the prognostic potential of GATA2 assessment in prostate cancer, we analyzed nuclear GATA2 expression on an annotated tissue microarray with 12,427 prostate cancer samples. Normal prostate glands were negative to weakly positive. GATA2 staining was found in almost all prostate cancers (95%). Strong GATA2 staining was linked to advanced tumor stage, high classical and quantitative Gleason grade (p \ 0.0001 each), positive nodal stage (p = 0.0116), and early biochemical recurrence (p \ 0.0001). GATA2 was linked to ERG-fusion-type cancers, with strong GATA2 staining in 29% of ERG-negative and 53% of ERG-positive cancers (p \ 0.0001). Separate calculations in 3854 cancers with and 4768 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. GATA2 expression was further linked to androgen receptor expression: Only 8% of androgen receptor-negative, but 56% of strongly androgen receptor expressing cancers had strong GATA2 expression (p \ 0.0001). In conclusion, the results of our study demonstrate that increasing GATA2 levels are linked to prostate cancer progression and aggressiveness. The prognostic value of GATA2 is remarkable in ERG-negative cancers. However, the upregulation of GATA2 in ERG-positive cancers makes it unsuitable as a prognostic marker in this patient subset.
The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer 
Introduction
In Western societies, prostate cancer is the most prevalent cancer in men. 1 A bulk of prostate cancers is indolent. Only a small subset is highly aggressive. 2, 3 Gleason grade and tumor extent on biopsies, prostate-specific antigen (PSA), and clinical stage are proven preoperative prognostic parameters. These data are statistically 1 powerful for the cohort, but often insufficient for individual treatment decisions. Thus, it is hoped that a better understanding of disease biology will lead to novel clinically applicable molecular markers that enable a reliable prediction of prostate cancer aggressiveness.
The transcription factor GATA2 is a member of a family of six proteins that have been named after their ability to bind specific DNA consensus sequences characterized by the A/T-GATA-A/G sequence. 4 GATA proteins function as pioneering factors that open chromatin to initiate tissue-specific expression programs. 5, 6 GATA2 was initially identified as a fundamental factor in early steps of hematopoiesis 7 because inactivating mutations of GATA2 were linked to myelodysplastic disorders and leukemia. 8, 9 However, later it became evident that GATA2 is also a critical factor for urogenital development 10 and specifically for the prostate gland.
11 GATA2 is a key transcription factor for the androgen receptor (AR) and is, in turn, transcriptionally regulated by AR and androgens in a negative feedback loop. 12 Furthermore, GATA2 modulates the transcriptional activity of androgen-responsive genes as it co-localizes on their DNA enhancer elements with AR and Fork head box protein A1. [12] [13] [14] [15] Thus, it was not surprising to find that experimental modulation of GATA2 levels in prostate cells had a strong impact on androgen-dependent transcription and cell growth. 13 Accordingly, studies investigating cohorts of 109 and 383 prostate cancers reported immunohistochemical GATA2 expression to be linked to aggressive tumor features such as invasive and metastatic cancers, 12, [16] [17] [18] high Gleason grade, and advanced tumor stage. 12, 16, 17 As such data identify GATA2 as a promising candidate for a clinically valuable prognostic marker, we studied the expression and prognostic impact of GATA2 in our large annotated prostate cancer prognosis tissue microarray (TMA), comprising more than 12,000 prostate cancer specimens.
Materials and methods

Patients
Radical prostatectomy specimens were available from 12,427 patients, who had surgery between 1992 and 2012. Median follow-up was 48 months (range: 1-280 months; Table 1 ). PSA recurrence was defined as the time point when postoperative PSA levels were at least 0.2 ng/mL and increasing at subsequent measurements. The TMA was annotated with tumor stage, Gleason grade, nodal stage, and resection margin status. The specimens were analyzed according to a standard procedure. 19 In addition to the classical Gleason categories, ''quantitative'' Gleason grading was performed as previously described. 20 In brief, every cancer demonstrating a Gleason 4 (and 5) pattern was subclassified according to its percentage of Gleason 4. For practical use, we subdivided the 3+4 and 4+3 cancers into seven subgroups: 3+4, ł 5% Gleason 4;  3+4, 6%-10%; 3+4, 11%-20%; 3+4, 21%-30%;  3+4, 31%-49%; 4+3, 50%-60%; and 4+3, 61%- 100%. In addition, separate groups were defined by the presence of a tertiary Gleason 5 pattern, including 3+4 Tertiary 5 and 4+3 Tertiary 5. The molecular database attached to this TMA contained results on ERG expression, ERG break-apart fluorescence in situ hybridization (FISH) analysis, 21 KI67 labeling index (Ki67LI) data, 22 and AR expression. 23 The use of archived leftover diagnostic tissues for manufacturing of TMAs and their analysis for research purposes, as well as patient data analysis, has been approved by local laws (HmbKHG, §12a) and by the local ethics committee (Ethics Commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.
Immunohistochemistry
Freshly cut TMA sections were all stained on the same day in a single run. Slides were deparaffinized, rehydrated, washed in DAKO buffer (K8002, Agilent, Santa Clara, CA) and transferred to a DAKO Link 48 autostainer device. GATA2 staining was performed with the rabbit polyclonal anti-GATA2 antibody (Cat. # NBP1-82581; Novus Biologicals Europe, Abingdon, UK) at 1:1350 dilutions. Heat-induced antigen retrieval was performed at 98°C in DAKO at pH 6. GATA2 staining was typically nuclear, sometimes with slight cytoplasmic co-staining. The staining intensity (0, 1+, 2+, and 3+) and the fraction of positive tumor cells were separately recorded for each tissue spot. A final score was then built from these two parameters according to the following system as previously described. 24 Negative cases had complete absence of staining, weak cases had staining intensity of 1+ in ł 70% of tumor cells or staining intensity of 2+ in ł 30% of tumor cells; moderate cases had staining intensity of 1+ in .70% of tumor cells, staining intensity of 2+ in .30% but in ł 70% of tumor cells or staining intensity of 3+ in ł 30% of tumor cells; strong cases had staining intensity of 2+ in .70% of tumor cells or staining intensity of 3+ in .30% of tumor cells.
Statistics
Contingency tables and the chi-square test were performed to search for associations between molecular parameters and tumor phenotype. Analysis of variance (ANOVA) test was applied to search for differences of the Ki67LI. Survival curves were calculated according to Kaplan-Meier. The log-rank test was applied to detect significant differences between groups. Cox proportional hazards regression analysis was performed to test the statistical independence and significance between pathological, molecular, and clinical variables. Separate analyses were performed using different sets of parameters available either before or after prostatectomy. Calculations were done with JMP 12 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 9769 (78.6%) of tumor samples were interpretable in our TMA analysis. Non-informative cases (2658, 21.4%) lacked tissue samples or unequivocal cancer tissue in the TMA spot. Normal prostate tissue showed negative to weakly positive nuclear staining. In cancers, nuclear GATA2 staining was seen in 9321 of 9769 (95.4%) samples and was considered weak in 12.2%, moderate in 43.5%, and strong in 39.7% (Table 2) . Representative images of GATA2 staining are shown in Figure 1 .
Association with TMPRSS2:ERG fusion status and ERG protein expression
To evaluate whether GATA2 expression is associated with ERG status in prostate cancers, we used data from previous studies (expanded from Minner et al. 21 ). Data on TMPRSS2:ERG fusion status obtained by FISH were available for 5896 tumors and by immunohistochemistry (IHC) for 8622 tumors with evaluable GATA2 staining. Data on both ERG FISH and IHC were available for 5676 cancers, and a concordant result (ERG IHC positive and break apart by FISH or ERG IHC negative and missing break apart by FISH) was found in 95% of cancers. GATA2 expression was linked to TMPRSS2:ERG rearrangement and ERG expression. For example, strong GATA2 staining was seen in 29% of ERG-IHC-negative but in 53% of ERG-IHC-positive cancers (p \ 0.0001) ( Figure 2 , Supplementary Tables 1  and 2 ). Table 2 ). These associations also held true in subset analyses of ERG-negative and ERG-positive cancers for ERG-positive cancers (Supplementary  Tables 1 and 2 ).
Association with AR
GATA2 is a known transcriptional regulator of AR expression. 13 We utilized IHC data on AR expression from a previous study 23 to compare AR and GATA2 expression levels. Data on both GATA2 and AR were available for 6448 cancers. There was a strong positive association between AR and GATA2 expression in all cancers, including both the ERG-negative and ERGpositive subsets (p . 0.0001 each; Figure 3 ).
Association with tumor cell proliferation (Ki67LI)
GATA2 was significantly linked to increased cell proliferation in all cancers, as measured by Ki67LI (p \ 0.0001). The average Ki67LI increased from 0.68 6 0.15 in cancers lacking GATA2 expression to 1.79 6 0.10 (weak), 2.82 6 0.05 (moderate), and 3.37 6 0.06 in cancers with strong GATA2 expression (p \ 0.0001). This association held true in all tumor subsets with identical Gleason score ( ł 3+3: p \ 0.0001, 3+4: p \ 0.0001, 4+3: p \ 0.0001, ø 4+4: p = 0.0007; Table 3 ). This relationship was more prominent in ERG-negative than in ERG-positive cancers (Supplementary Tables 3 and 4) . 
Association with PSA recurrence
Follow-up data were available for 8787 patients with interpretable GATA2 staining. Highly significant associations were found between early PSA recurrence and GATA2 expression in all tumors (Figure 4(a) , p \ 0.0001) as well as in the subgroup of ERG-fusionnegative cancers (Figure 4(b) , p \ 0.0001), whereas GATA2 was unrelated to patient prognosis in the subgroup of ERG-fusion-positive cancers (p = 0.1960; Figure 4 (c)). Because of the similar behavior of cancers with negative/weak and moderate/strong staining, the GATA2 results were grouped into low (negative/weak) and high (moderate/strong) staining for further analyses. To estimate the impact of the Gleason grade on the prognostic power of GATA2 in ERG-negative cancers, we performed further subset analyses in cancers with identical classical (Figure 5 
Multivariate analysis
Four different types of multivariate analyses were performed evaluating the clinical relevance of GATA2 expression in different scenarios (Table 4) . Scenario 1 evaluated all postoperatively available parameters including pathological tumor stage, pathological lymph node status (pN), surgical margin status, preoperative PSA value, and pathological Gleason grade obtained after the morphological evaluation of the entire resected prostate. In scenario 2, all postoperatively available parameters with exception of nodal status were included. The rationale for this approach is that the indication and extent of lymph node dissection is not standardized in the surgical treatment of prostate cancer and that excluding pN in multivariate analysis can markedly increase case numbers. Two additional scenarios had the purpose of modeling the preoperative situation as much as possible. Scenario 3 included GATA2 expression, preoperative PSA, clinical tumor stage (cT stage), and Gleason grade obtained on the prostatectomy specimen. Since postoperative determination of a tumor's Gleason grade is ''better'' than the preoperatively determined Gleason grade (subjected to sampling errors and consequently under-grading in more than one-third of cases 25 ), another multivariate analysis was added. In scenario 4, the preoperative Gleason grade obtained on the original biopsy was combined with preoperative PSA, cT stage, and GATA2 expression. These analyses revealed that GATA2 provided independent prognostic information in ERG-negative scenarios (hazard ratio 1.26-1.48, Supplementary Table 5 ), especially if the lymph node stage was not included. An independent prognostic value of GATA2 was lacking in ERG-positive cancers.
Discussion
The results of our study demonstrate that overexpression of GATA2 is linked to adverse tumor features and early biochemical recurrence in the subset of prostate cancers lacking ERG fusion.
Detectable nuclear GATA2 staining was found in virtually all-normal and cancerous prostate samples in our study. However, unequivocal upregulation in cancers as compared to normal glands, that is, moderate to strong staining was seen in more than 83.2% of our 9769 interpretable cancers. The total fraction of 95% cancers with detectable GATA2 staining in our study is slightly higher than in earlier studies on 109 and 383 prostate cancers, who reported positive staining in 77%, 82%, 84%, and .90% of cancers.
12,16-18 These differences are remarkably small given that various antibodies (i.e. a mouse monoclonal antibody from Sigma, rabbit polyclonal antibodies from Cell Signaling Technology, and Novus) and laboratory protocols were used. It is possible that the Novus antibody used in our study resulted in a particularly sensitive detection of the ubiquitously expressed GATA2 protein. Chiang et al. 18 reported .90% positivity in their TMA study on 358 tumors with the same antibody. He et al. 12 reported increased staining intensity of cancer cells as compared to normal epithelium. Together, these findings demonstrate that upregulation of GATA2 expression typically accompanies malignant transformation of prostate cells.
A strong association with tumor phenotype and clinical outcome was found in this study. This is in concordance with earlier work reporting associations between increased GATA2 expression and one or more adverse tumor features including advanced stage, high Gleason grade, metastatic growths, and early biochemical recurrence in univariate analysis. 12, 16, 17 A higher cancer aggressiveness in case of GATA2 overexpression fits well with the known roles of GATA2 as an inducer of AR expression and an enhancer of transcription of androgen-responsive genes. 12, 17 As summarized in a recent review by Rodriguez-Bravo et al., 26 GATA2 acts through three modes of action on a genome-wide level: GATA2 binds to upstream AR regulatory elements to enhance AR expression, creates open chromatin in AR enhancers by recruiting the p300 histone acetyltransferase that activates chromatin via acetylation of H3K27, and forms and maintains regulatory chromatin loops between AR-bound distal enhancers and AR target gene promoters via recruitment of the mediator coregulatory complex subunit MED1. The central role of the AR for prostate cancer is well known from studies showing that the administration of androgen results in accelerated tumor growth in vitro, 27 and in vivo. 28 The availability of a molecular database attached to this prostate cancer TMA enables us to investigate the interaction with genes of interest including the AR and TMPRSS2:ERG fusions. The latter occur in about 50% of prostate cancers as a consequence of chromosomal proximity induced by AR signaling. 29 The striking correlations between the levels of GATA2 and AR expression as well as presence of ERG fusion were expected based on in vitro data demonstrating that ERG is a physiological upstream regulator of GATA2 during hematopoiesis, 30 while AR is a direct transcriptional target of GATA2. 12 Our findings are further corroborated by He et al., 12 who also reported significant associations between expression of GATA2, AR, and ERG in 383 prostate cancers. Further in line with the study of He et al., we found elevated tumor cell proliferation (KI67 LI) in cancers with GATA2 overexpression, which fits well with functional studies demonstrating that GATA2 gene silencing greatly inhibited proliferation of LNCaP prostate cancer cells.
18
TMPRSS2:ERG fusions predominantly occur in younger patients 23, 31 and lead to a constitutive overexpression of the transcription factor ERG.
32 ERG overexpression by itself completely lacks prognostic relevance, at least in patients not receiving systemic therapy. 22 However, ERG modulates the expression of more than 1600 genes in prostate epithelial cells. 33 The biological effects of various proteins may be mitigated or intensified in such a modified cellular microenvironment, which may serve as an explanation for the selective prognostic role of GATA2 expression in ERG-negative cancers. Also, in earlier studies, we had observed molecular features that were either prognostic in ERG-positive 34, 35 or in ERG-negative cancers 36, 37 but not in both groups. Although it cannot be excluded that our experimental setup was better suited to distinguish expression differences in cancers with lower expression levels (ERG-negative cancers) than in those with higher expression (ERGpositive cancers), our data demonstrate that the role of prognostic markers may largely depend on individual molecular tumor features. This represents a challenge for the development of prognostic cancer tests that should be applicable to every patient.
The data of this study suggest that GATA2 expression may represent a clinically useful marker in ERGnegative cancer. In this subgroup, GATA2 expression had a prognostic impact that was independent of established prognostic parameters, especially if only parameters were included that are available at the moment in time when decisions on therapy are taken. Earlier studies of 109 and 383 prostate cancers had also demonstrated a statistically significant prognostic impact of GATA2 overexpression, but could not demonstrate an independent prognostic effect of GATA2 overexpression 12, 16 and were unable to separately analyze molecularly defined subgroups. This highlights the importance of large tumor sets that allow for statistically meaningful analyses. It is of note that several parameters that are usually included in multivariate analyses are statistically strong but suffer from significant shortcomings in clinical practice. pT stage and nodal status are lacking during the preoperative therapeutic decision-making. The Gleason grade, the most powerful preoperatively available prognostic marker, suffers from very substantial interobserver variability reaching beyond 40% in individual biopsies. 38 That GATA2 expression had a prognostic impact in Gleason 3+4 = 7 cancers illustrates that this subgroup contains highly diverse tumors ranging from Gleason 3+4 = 7 with 5% Gleason 4 and behaving very similar to Gleason 3+3 = 6 up to Gleason 3+4 = 7 with 40% Gleason 4 and aggressive tumor behavior more comparable to Gleason 4+3 = 7.
20 Accordingly, GATA2 expression lacked prognostic impact in cancers defined by identical quantitative Gleason grade. This demonstrates the power of the quantitative Gleason grading system, which is, however, not universally applied and does not solve all issues of interobserver variability in prostate cancer grading. GATA2 expression measurement may thus have potential to become an element in a future multiparametric prognostic test for ERG-negative prostate cancer.
Recent studies suggest that GATA2 may also serve as a predictive biomarker particularly in advanced and castration-resistant prostate cancers. For example, Vidal et al. 39 demonstrated that GATA2 overexpression is linked to chemotherapy resistance in vitro, and that GATA2 knockdown can reduce tumor growth in patient-derived, castration-resistant, taxane-resistant xenografts. Although direct inhibitors of GATA2 are currently not available, indirect targeting may be achieved through inhibitors of upstream or downstream factors such as NOTCH, AKT or Hedgehog signaling, histone acetyltransferases, and deacetylases, where inhibitory compounds are under development (reviewed in Rodriguez-Bravo et al. 26 ). The high fraction of about 80% of cancers with GATA2 upregulation suggests that many prostate cancer patients may benefit from such therapies should they become available.
In summary, our study demonstrates that GATA2 upregulation is a frequent event in prostate cancer, which is linked to poor prognosis specifically in the subset of ERG-negative cancers. GATA2 expression analysisespecially in combination with other prognostic markers-may have the potential for clinical application in prostate cancer. 
